GENF Genflow Biosciences Plc

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

21 March 2024

Genflow Biosciences Plc 

Announces Publication of a Key European Patent in Partnership with University of Rochester, New York, et al.

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is pleased to announce a significant milestone in its journey. Genflow's collaborative partners, including the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine, have received confirmation that their European patent application was published today by the European Patent Office, bearing the reference number EP 4 338 267.

Innovation in Age-Related Disease Prevention and Treatment

The patent, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," enhances the understanding and potential treatment of diseases associated with aging by focusing on the SIRT6 gene/protein, known for its critical role in DNA repair, metabolism, and longevity.

SIRT6 regulates DNA damage repair, specifically double strand breaks (DSB) and prevents or delays aging of cells. Genflow's lead drug candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene. Genflow is currently undertaking key Investigational New Drug (IND)-enabling development activities that will help define the pharmacological and toxicological properties of GF-1002 and its potential benefits, initially, for non-alcoholic steatohepatitis (NASH) patients.

In 2023, the Company received positive feedback from the Federal Agency for Medicines and Health Products in Belgium and expects a follow-up meeting in Q2 2024 to finalise design of Phase/II clinical trials. NASH, the most severe form of non-alcoholic fatty liver disease (NAFLD) characterized by excessive fat deposits in the liver, is usually a silent disease with few, if any, symptoms, and effective treatments.

Dr. Eric Leire, CEO of Genflow commented: "This approval from the European Patent Office highlights the innovative spirit of our collaborative team and we are incredibly proud to be part of this pioneering research alongside such respected institutions." He continued, "This patent represents a leap forward in our understanding and capabilities in treating age-related conditions and marks a significant step forward in our mission to develop effective therapies for NASH and other age-related diseases."

Contacts

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating non-alcoholic steatohepatitis (NASH), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com  and follow the Company on LinkedIn and Twitter/X.

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation